IMAAVY trial data has been generated, supporting the submission of a Biologics License Application (BLA) to the U.S. FDA.
4 reports, 2 independent
Updated Aug 27
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
IMAAVY trial data has been generated, supporting the submission of a Biologics License Application (BLA) to the U.S. FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA expands Imaavy label; J&J pursues acquisition of Momenta Pharmaceutic.1 source
IMAAVY trial data supports BLA submission to the U.S. FDA.1 source
Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer